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Abstract 
Background: The soluble CD14 subtype, Presepsin, appears to be an accurate sepsis diagnostic marker, but data 
from intensive care units (ICUs) are scarce. This study was conducted to evaluate the diagnostic and prognostic value 
of Presepsin in ICU patients with severe sepsis (SS), septic shock (SSh) and severe community-acquired pneumonia 
(sCAP).
Methods: Presepsin and procalcitonin (PCT) levels were determined for patients at admission to ICU. Four groups 
have been differentiated: (1) absence or (2) presence of systemic inflammatory response syndrome, (3) SS or (4) SSh; 
and 2 groups, among the patients admitted for acute respiratory failure: absence or presence of sCAP. Biomarkers 
were tested for diagnosis of SS, SSh and sCAP and for prediction of ICU mortality.
Results: One hundred and forty-four patients were included: 44 SS and 56 SSh. Plasma levels of Presepsin and PCT 
were significantly higher in septic than in non-septic patients and in SSh as compared to others. The sepsis diagnostic 
accuracy of Presepsin was not superior to that of PCT (AUC: 0.75 vs 0.80). In the 72/144 patients admitted for acute 
respiratory failure, the capability of Presepsin to diagnose sCAP was significantly better than PCT. Presepsin levels were 
also predictive of ICU mortality in sepsis and in sCAP patients.
Conclusion: Plasma levels of Presepsin were useful for the diagnosis of SS, SSh and sCAP and may predict ICU mor-
tality in these patients.
Keywords: Severe sepsis, Septic shock, Diagnosis, Prognosis, Presepsin, Procalcitonin, Community-acquired 
pneumonia
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Background
Despite advances in therapy, sepsis is the leading cause 
of death in critical care settings [1]. To improve the sur-
vival, early recognition of severe sepsis and septic shock 
and subsequent introduction of an aggressive support-
ive therapy are mandatory [2]. In routine clinical prac-
tice, early anti-infection treatment should be given 
before definitive diagnosis since blood culture, the gold-
standard diagnostic method, usually takes several days 
to obtain the results and frequently yields low positive 
results. In fact, adequate microbiological information, 
ensuring appropriate therapy and avoiding unnecessary 
or unduly prolonged therapy, is lacking in more than 50 % 
of clinical situations. In this purpose, novel biomarkers 
have been developed and are being widely adopted in 
clinical settings. Among these biomarkers, procalcitonin 
(PCT) and high-sensitivity C-reactive protein (hs-CRP) 
are the main diagnostic markers used for bacterial sep-
sis. PCT is known to have the highest specificity, but its 
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levels may increase in conditions without bacterial infec-
tion, such as severe trauma, invasive surgical procedure 
and critical burn injuries, thus resulting in false-positive 
results [3–5].
More recently, the soluble CD14 subtype, Presepsin, 
appears to be an accurate sepsis diagnostic marker and 
rises up a great clinical interest. Levels of Presepsin were 
found significantly higher in septic than in non-septic 
patients or those with SIRS [6]. Moreover, a specific 
increase was reported in the early stage of sepsis that 
also well correlated with severity [7]. Accordingly, plasma 
Presepsin levels could be useful for diagnosis and prog-
nosis of sepsis and also for monitoring the course of the 
disease [8, 9]. Most of these studies have been, however, 
performed in settings of emergency departments [10–
13], and data from intensive care units (ICUs) are scarce. 
Also, few studies have focused on community-acquired 
pneumonia [14–16]. In addition, plasma concentrations 
of Presepsin in most of previous reports were determined 
by ELISA method, which is time-consuming and not 
suitable for emergency. Yet, the new development of a 
fully automated point of care assay for rapid whole-blood 
Presepsin measurement updated its clinical use in emer-
gency and ICUs [8, 11, 17].
Therefore, this study aimed to evaluate the diagnostic 
and prognostic utility of Presepsin measurements using 
the new fast method in severe sepsis and septic shock 
intensive care unit (ICU) patients. We also aimed to eval-
uate the diagnostic and prognostic utility of Presepsin 
measurements for severe community-acquired pneumo-
nia (sCAP) in the subgroup of patients admitted to the 
ICU with acute respiratory failure.
Methods
This observational prospective study was performed 
at 2 ICUs of Lapeyronie and Gui de Chauliac Univer-
sity hospitals of Montpellier, France. These two ICUs 
admit preferentially patients with suspected infectious 
diseases. It was carried out according to the principles 
of the Declaration of Helsinki and was approved by the 
Ethic Committee of Montpellier (Comité de protection 
des Personnes: CPP du CHU de Montpellier). Written 
informed consent was obtained from all participating 
patients or their closest relatives or legal representatives.
Study population
All consecutive patients admitted to ICUs from Janu-
ary to May 2014 were included. Exclusion criteria were 
pregnancy, age < 18 years, previous congestive heart fail-
ure (class NYHA ≥ III), right ventricular failure, chronic 
renal failure stage III KDOQI or more, hepatic failure 
and acute pulmonary embolism.
Methods
Baseline clinical variables including age, gender, cause of 
sepsis, and comorbidities were collected. The severity of 
disease was assessed by SAPS II [18] and SOFA scores 
[19]. At ICU admission, clinical and biological parame-
ters including mean arterial pressure (MAP), serum cre-
atinine, hsCRP, and PCT were also collected. ICU length 
of stay was recorded; ICU and in-hospital mortality were 
assessed.
Diagnosis of systemic inflammatory response syn-
drome (SIRS) and of sepsis severity was based on 
established criteria of the American College of Chest 
Physicians/Society of Critical Care Medicine [20]. 
Microbiological cultures were carried out. Patients who 
revealed a microbiologically or clinically proven infection 
were assigned to the sepsis group, and the others were 
considered as non-septic. Infection was considered clini-
cally proven if the clinical picture and evolution complied 
with the diagnosis and if the patient was appropriately 
treated by antibiotics.
Community-acquired pneumonia (CAP) was defined 
as the presence of a new infiltrate on a chest radiograph 
and at least one of the following signs: cough, sputum 
production, dyspnea, core body temperature  >  38.0  °C, 
auscultatory findings of abnormal breath sounds and 
rales [21]. Diagnosis may be confirmed by antigenuria or/
and sputum cultures. Severe CAP (sCAP) was defined 
according to the American Thoracic Society guidelines 
[21].
Venous samples were taken from all patients at admis-
sion and immediately performed for Presepsin, PCT 
and hsCRP measurements. Presepsin concentration 
was measured by a chemiluminescent enzyme immu-
noassay (CLEIA) on a compact automatized immuno-
analyzer PATHFAST® (Mitsubishi Chemical Medience, 
Japan) recently evaluated [17]. The reference interval 
of the PATHFAST Presepsin assay determined from 
127 healthy volunteers ranged from 92.7 to 398  pg/
mL with an arithmetic mean of 189  pg/mL Presepsin 
values [17]. PCT was measured by commercial chemi-
luminescence assay on Kryptor® immunoanalyzer (Ther-
moFisher, Agnières, France) following the manufacturers’ 
instructions. Determination of hsCRP was run on the 
Cobas8000/e502® analyzer (Roche Diagnostic, Meylan, 
France) using immunoturbidimetric method.
Two study physicians (KK and VG) independently 
reviewed all available clinical, biological and radiological 
patients’ data and classified all patients into four disease 
groups: absence (non-SIRS) or presence of SIRS, severe 
sepsis (SS) or septic shock (SSh). The two study physi-
cians followed recommended definitions and algorithms 
(20). Briefly, patients with SIRS and positive cultures 
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were considered as septic. When cultures were non-con-
tributive, clinical and biological picture (site of infection, 
clinical and biological picture and evolution), successful 
treatment by antibiotics and rule out of other diagnosis 
were main elements of sepsis diagnosis. Among the sub-
group of patients who were admitted for acute respira-
tory failure, they reviewed also their data and classified 
them into two disease groups: absence or presence of 
sCAP (even in the absence of identified causative agent). 
When the study physicians cannot statute on the pres-
ence or not of sepsis, the patient was not included in 
the study. The study physicians and those on charge 
of patients were blinded to the results of Presepsin and 
PCT.
Statistical analysis
The statistical analyses were performed using the STAT-
VIEW II (Abacus Concepts Inc, Berkeley, CA). We first 
performed a descriptive analysis by computing the fre-
quencies and the percents for categorical data, means, 
standard deviations, quartiles and extreme values for 
continuous data. We also checked for the normality of 
the continuous data distribution using the Shapiro–Wilks 
tests. We compared septic to non-septic patients and 
patients with and without sCAP for Presepsin, CRP and 
PCT measurements. The univariate analysis was per-
formed using two-tailed Student’s t test, or two-tailed 
Mann–Whitney–Wilcoxon’s test when appropriate. 
Results were adjusted for multiple comparisons using 
Bonferroni’s method. Levels of significance for all tests 
were set at p  <  0.05. Sensitivity, specificity and positive 
predictive value (PPV) and negative predictive value 
(NPV) of Presepsin and PCT for the diagnosis of sep-
sis and pneumonia were calculated using final diagnosis 
categorization based on clinical data, clinical scores and 
routinely used biomarkers levels. A receiver operating 
characteristic (ROC) analysis was performed for each 
of the biomarkers, and their diagnostic performance for 
sepsis and for other pathological condition was com-
pared. The optimal threshold value was set for each ROC 
curve through the Youden Index (corresponding to the 
maximum of the sum “sensibility + specificity”). Mortal-
ity was displayed as Kaplan–Meier (log-rank test) plots 
according to the quartiles of Presepsin levels.
Results
Study population
During the study period, a total of 222 critically ill 
patients were admitted in ICUs. After the exclusion of 
78 patients, 144 were included: 88 males and 56 females. 
One hundred patients conformed to the criteria of bac-
terial sepsis: 44 with SS and 56 with SSh. Among the 44 
non-septic patients, 19 were assigned for non-SIRS and 
25 for SIRS. The screening process is shown in Fig. 1. The 
two study physicians were on total agreement on review-
ing patient’s data (kappa = 1).
Patient’s baseline characteristics are summarized in 
Table 1. Non-septic and septic patients did not differ in 
age, sex, SAPS II score and current clinical and biologi-
cal parameters, except for SOFA scores that were signifi-
cantly higher in septic group. Forty of 100 septic patients 
experienced positive blood cultures. Severe pneumonia 
represented 58  % of sepsis causes (Table  2). Analyzing 
only the subgroup of patients (72) admitted for acute res-
piratory failure (ARF), sCAP was then diagnosed in 58 of 
them. Age and sex were not different between patients 
with infectious and non-infectious ARF, but SAPS II and 
SOFA scores were significantly higher in the infectious 
group (Table 3).
Presepsin, PCT measurements
Significantly higher levels of hsCRP and PCT were found 
in septic as compared to non-septic patients (Table  1). 
Presepsin blood levels were also significantly more ele-
vated in septic patients. Though Presepsin levels were 
significantly higher in septic as compared to non-septic 
patients, we observed non-significant differences in these 
levels between SIRS and severe sepsis groups (p = 0.574). 
In contrast, they were significantly higher in SSh versus 
SS and SIRS groups (Fig. 2a). Similar results were found 
regarding PCT levels (Fig. 2b). We extended our analysis 
to patients admitted for ARF and found that both Prese-
psin and PCT levels were significantly higher in patients 
with sCAP (Fig. 2c, d).
Diagnostic accuracy and cutoff value of Presepsin
The ROC curves were designed including those patients 
with a diagnosis of SS/SSh and are shown in Fig. 3a. The 
AUCs (areas under the curve) calculated from ROC 
curves were 0.75 for Presepsin and 0.80 for PCT, whereas 
those of SAPS II (0.57) and SOFA (0.64) were lower 
(Fig.  3a). When we combined Presepsin and PCT, AUC 
was at 0.84 (Fig.  3a). At a cutoff value of 466.5  pg/mL, 
sensitivity and specificity of Presepsin to severe sepsis 
and septic shock diagnosis were 90 and 55 %, respectively 
(Table  4). Lower sensitivity (80  %) and higher specific-
ity (59  %) were observed for PCT (cutoff value: 0.5  pg/
mL). The combination of Presepsin and PCT significantly 
improved specificity and PPV (Table 4).
The ROC curves were also designed including those 
patients admitted with ARF showed that the diagnos-
tic value of Presepsin to discriminate infectious (sCAP) 
and non-infectious respiratory failure (AUC = 0.85) was 
higher than that of PCT (0.79), SAPS II (0.72), SOFA 
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(0.78) scores, and similar to that of the combination 
of Presepsin and PCT (0.84) (Fig.  3b). Using a cutoff of 
Presepsin at 588  pg/mL, sensitivity (81  %), specificity 
(80  %), NPV and PPV values are greater than those of 
PCT (Table  4). The combination of Presepsin and PCT 
improved specificity, NPV and PPV reaching up to 97 %.
222 Paents admied to ICUs
january-may 2014
78 paents excluded:
28 for exclusion criteria
20 refused to consent
22 for undetermined diagnosis of sepsis
8 for missing data
Study populaon
n = 144 















Fig. 1 Flowchart for the study population. SIRS systemic inflammatory systemic response, ARF acute respiratory failure, NIRF non-infectious respira-
tory failure, sCAP severe community-acquired pneumonia
Table 1 Patient characteristics
Comparison between septic and non-septic patients
SAPS simplified acute physiology score, SOFA sequential organ failure assessment score, PCT procalcitonin, hsCRP high-sensitivity C-reactive protein








Sex (male/female) 88/56 27/17 61/39 ns
Age, years (mean ± SD) 58 ± 17.5 57.5 ± 20.1 58.3 ± 16 0.907
SAPS II, median (IQR) 47 (33–62) 44 (27–60) 48 (36–64) 0.176
SOFA, median (IQR) 8 (6–11) 6 (4–10) 8 (6–11) 0.008
Creatininemia, median (IQR), (μmol/L) 68 (27–102) 80 (29–107) 57 (26–101) 0.419
hsCRP, median (IQR), (mg/L) 108 (38–133) 31 (5–87) 180 (81–284) <0.0001
PCT, median (IQR), (ng/mL) 1.89 (0.32–13.7) 0.3 (0.1–0.9) 4.7 (0.8–20.5) <0.0001
Presepsin, median (IQR), (pg/mL) 1058 (510–2090) 454 (315–915) 1432 (773–2337) <0.0001
ICU length of stay (IQR), (days) 4 (2–10) 3 (1–7) 5 (2–11) 0.04
ICU mortality, n (%) 34 (23.6) 9 (20.4) 25 (25) ns
In-hospital mortality, n (%) 38 (26.3) 10 (22.7) 28 (28) ns
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Prognostic value of Presepsin levels
Of the 100 septic patients included in the study, 25 (25 %) 
died during ICU stay. Deceased septic patients showed 
significantly higher Presepsin, PCT levels and severity 
scores at ICU admission (Table 5). After thirty ICU days, 
Kaplan–Meier curve assessing the impact of Presep-
sin levels on survival among critically ill septic patients 
did not show any differences according to the quartile of 
Presepsin levels (Fig. 4a). However, at a cutoff Presepsin 
value of 1926  pg/mL, mortality of septic patients was 
significantly higher in those with upper levels (Fig.  4b). 
Among the 58 patients with sCAP, 15 died at the ICU 
(mortality: 26 %). Plasma levels of Presepsin and PCT as 
well as SAPS II and SOFA scores were significantly higher 
in non-survivors patients (Table 6). Kaplan–Meier curves 
showed that patients with Presepsin of the upper quar-
tile had significantly the highest mortality (Fig.  4c). The 
best cutoff value of Presepsin level to discriminate sur-
vivors from non-survivors was at 714 pg/mL (p = 0.04) 
(Fig. 4d).
Discussion
At ICU admission, plasma levels of Presepsin were found 
to be significantly higher in critically ill patients with 
sepsis in comparison with those without sepsis. Presep-
sin plasma levels of SIRS and SS patients were not sig-
nificantly different, but patients with SSh had significant 
higher levels as compared to others. The sepsis diagnostic 
accuracy of Presepsin was not superior to that of PCT. 
With the combination of Presepsin and PCT, specificity 
and predictive positive value for sepsis were enhanced. 
We also demonstrated the usefulness of Presepsin for 
the diagnosis of sCAP in settings of ARF with an even 
better accuracy than PCT. Also, plasma Presepsin lev-
els best predict ICU mortality in septic patients and 
those with sCAP at cutoff values of 1925 and 714 pg/mL, 
respectively.
It is now well demonstrated that sepsis, especially SS 
and SSh, should be diagnosed early and treated within 1 h 
after diagnosis [22]. Consequently, early sepsis biomark-
ers with a high sensitivity and specificity are required 
in addition to rapid detection methods. PCT, quickly 
measurable, is the most studied biomarker and is one 
allowing early diagnosis and management of therapy [4]. 
Presepsin is released, after intravenous administration 
of endotoxin in healthy patients, earlier than PCT [23–
26], within the first 2 h. It reached a maximum after 3 h 
Table 2 Causes of infection in the 100 septic patients










Table 3 Characteristics of the subgroup of patients admitted for acute respiratory failure
Comparison between patients with infectious (pneumonia) and non-infectious respiratory failure (NIRF) at admission to ICU
ARF acute respiratory failure, SAPS simplified acute physiology score, SOFA sequential organ failure assessment score, hsCRP high-sensitivity C-reactive protein, PCT 
procalcitonin, LOS length of stay








Sex (male/female) 47/25 9/5 38/20 0.41
Age, years (mean ± SD) 61.7 ± 13.3 62.4 ± 13.4 61.6 ± 13.3 0.39
SAPS II, median (IQR) 47 (34–62) 37.5 (24–48) 48 (35–66) 0.01
SOFA, median (IQR) 8 (6–11) 5 (3–7) 9 (7–11) 0.0007
Creatininemia, median (IQR), (μmol/L) 60 (37–101) 86 (67–105) 50 (33–101) 0.22
Positive HAA, n 16 0 16
hsCRP, median (IQR), (mg/L) 106 (51–245) 36 (23–105) 136 (71–270) 0.007
PCT, median (IQR), (ng/mL) 1.05 (0.28–8.84) 0.13 (0.09–0.34) 1.8 (0.3–11.4) 0.0006
Presepsin, median (IQR), (pg/mL) 989 (513–1951) 322 (231–534) 1209 (674–2195) <0.0001
ICU LOS, median (IQR), (days) 5 (3–11) 4 (3–7) 6 (3–12) 0.21
ICU mortality, n (%) 15 (21) 1 (7) 14 (24) 0.01
In-hospital mortality, n (%) 18 (25) 2 (14.2) 16 (27.5) 0.04
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and returns to baseline concentrations after 4–8  h [27]. 
Indeed, higher blood levels of Presepsin were reported 
in infected patients as compared to non-infected and 
increased sequentially from SIRS, local infection to 
severe sepsis group [8]. In patients presenting to the 
emergency department, Liu et al. [10] demonstrated that 
Presepsin levels had the best capacity for diagnosis of 
sepsis at every stage, but Ulla et al. [13] reported a lower 
diagnostic value as compared to PCT. In this study, we 
enrolled exclusively critically ill patients admitted to ICU 
Fig. 2 Comparison of Presepsin and PCT levels at ICU admission in all patients (a, b, respectively) and in the 72 patients with acute respiratory fail-
ure: infectious versus non-infectious origin (c, d, respectively). SIRS systemic inflammatory systemic response, NSIRS non-SIRS, S Sepsis severe sepsis, S 
shock septic shock, NIRF non-infectious respiratory failure
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with potential concomitant organ failures and associated 
pathologies making differences between severe sepsis and 
SIRS inconsiderable. We found that Presepsin levels were 
not significantly different between SS and SIRS patients 
but significantly higher in SSh patients as compared to 
others. Median Presepsin concentrations at admission 
to the ICU of patients with SSh were at around 2000 pg/
mL comparables to those reported by Liu et al. [10] and 
Carpio et  al. [11] but differed from Ulla et  al. [13] who 
reported higher values. Studying 116 severe sepsis and 
septic shock patients during their first week of ICU treat-
ment, Behnes et  al. [7] observed an increasing trend of 
Presepsin levels compared to controls from the lowest 
to the highest groups of sepsis severity. They also found, 
at day 1 of ICU treatment, that the value of Presepsin to 
diagnose septic shock (AUC = 0.80) was comparable to 
that of PCT (AUC = 0.83). The plotted ROC curves for 
our patients showed that the AUC for Presepsin was 0.75, 
less than PCT (0.80). In contrast, other studies showed 
that Presepsin has a better sensitivity and specificity in 
the diagnosis of sepsis than other biomarkers with an 
AUC at 0.845 (PCT: 0.65) [8]. Its sensitivity increased 
from 80.3 to 87.8  % and specificity from 78.5 to 81.4  % 
when the cutoff value was set from 399 to 600 pg/mL. In 
a multicenter study, the sensitivity of Presepsin for the 
diagnosis of sepsis was even higher at 91.9 %, significantly 
higher than PCT (89.9 %), IL6 (88.9 %) and blood cultures 
(35.4 %) [9]. A recent analysis of 246 patients admitted to 
the ICU reported a highest AUC of Presepsin at 0.948 
but less than that of PCT (0.989) [28]. Presepsin cut-
off levels to sepsis diagnosis varied from 400 to 600 pg/
mL in emergency department settings but were above 
Fig. 3 Receiver operating characteristic (ROC) for Presepsin, PCT, SAPS II and SOFA for diagnosis of sepsis (severe sepsis or septic shock) in all 
patients (a) and for diagnosis of pneumonia (infectious respiratory failure) in patients admitted for acute respiratory failure (b). SAPS simplified acute 
physiology score, SOFA sequential organ failure assessment score, PCT procalcitonin
Table 4 Sensitivity, specificity, positive predictive value 
(PPV) and negative predictive value (NPV) of PCT and Pre-
sepsin and their combinations for severe sepsis and septic 
shock and for pneumonia diagnoses
SS severe sepsis, SSh septic shock, PPV positive predictive value, NPV negative 
predictive value
a Cutoff value for PCT at 0.5 ng/mL
b Cutoff value for Presepsin at 466 pg/mL
c Cutoff value for Presepsin at 588 pg/mL
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
SS and SSh
 PCTa 80 59 82 57
 Presepsinb 90 55 82 71
 PCT and Prese-
psin
75 68 85 55
Pneumonia
 PCTa 69 80 93 40
 Presepsinc 81 80 94 52
 PCT and Prese-
psin
62 93 97 62
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500 pg/mL in ICU settings [7, 8]. At a diagnostic cutoff 
set at ≥466.5  pg/mL, we observed that Presepsin had a 
higher sensitivity (91 vs 80 %) and a lower specificity (55 
vs 59  %) than PCT. Its diagnostic accuracy significantly 
improved when combined with PCT. Of note, a recent 
meta-analysis of accuracy of Presepsin for the diagnosis 
of sepsis included 8 studies investigating a total of 1815 
patients (1165 sepsis and 525 SIRS) and showed that its 
AUC was 0.89 with a specificity at 78 % and a sensibility 
at 86 % but failed to determine the optimal cutoff value 
[16]. Presepsin was found suitable for the assessment of 
severity and prognosis of sepsis as well. At a cutoff value 
of 1925 pg/mL, its levels were predictive of ICU mortality 
in our septic patients. In the ALBIOS trial, a first analy-
sis included 100 patients with SS and SSh, showing that 
median concentration of Presepsin at ICU admission was 
2269 (1171–4300)  pg/mL in deceased patients, which 
was significantly higher than 1184 (875–2113) pg/mL in 
survived [29]. Another study showed that Presepsin was 
better than IL6, CRP and PCT in assessing the risk of 
death within 30 days after onset of sepsis [10]. It was also 
shown that Presepsin had a valuable prognostic capacity 
to predict long-term all-cause mortality [7]. In addi-
tion, Presepsin levels were found to be correlated with 
APACHE II and SOFA scores [7] and to the appropriate-
ness of antibiotherapy [29, 30]. Indeed, the second analy-
sis from the ALBIOS trial (997 patients with severe sepsis 
or septic shock) demonstrated that Presepsin level was 
independently associated with the number and degree of 
organ dysfunctions or failures, coagulation disorders and 
ICU mortality [30].
More than half (58  %) of our septic patients have a 
sepsis from pulmonary origin. Diagnosis and severity of 
CAP are difficult and largely depend on the clinician’s 
experience since they are based on clinical and radiologi-
cal arguments [31–33]. Circulating levels of PCT con-
sidered in the initial assessment of patients with signs 
and symptoms suggestive of CAP have a high predictive 
value in its clinical risk assessment and appear to be more 
specific for bacterial etiologies [34–36]. However, sev-
eral observations suggest that PCT may vary with sev-
eral factors including age, liver or renal dysfunction [36]. 
Some authors suggested that PCT should be regarded 
as a prognostic rather than a diagnostic factor [1, 37, 
38]. Investigating more than 570 patients with CAP at 
the emergency department, Liu et al. [14] observed that 
Presepsin level was significantly higher in sCAP patients 
than in CAP patients and was predictive of mortality and 
that its combination with CURB65 score best predicted 
diagnosis and 28-day mortality. Our results extended 
these observations in ICU settings and demonstrated 
that Presepsin levels may be helpful in the identification 
of the infectious origin of an ARF. Moreover, the com-
bination of Presepsin and PCT significantly improves 
their diagnostic value. Finally, we observed that Presepsin 
might also help to early stratify the risk and the prognosis 
of sCAP.
We must acknowledge some limitations to our study. 
First, our study was a bi-center study, and the results may 
not be directly applicable to all ICUs. Second, our pop-
ulation included a relative limited number of patients. 
Third, only plasma Presepsin levels at ICU admission 
were determined and dynamic and follow-up changes 
of this biomarker were not investigated [7]. Fourth, the 
diagnosis accuracy of Presepsin level may be affected by 
kidney function. Indeed, Nagata et  al. [39] have shown 
an increase in Presepsin levels with decline in renal 
Table 5 Comparison of  clinical and  biological variables 
at ICU admission between survivor and non-survivor sep-
tic patients
SAPS simplified acute physiology score, SOFA sequential organ failure 
assessment score, PCT procalcitonin, hsCRP high-sensitivity C-reactive protein






Sex (male/female) 43/32 18/7 0.06
Age, years (mean ± SD) 56.2 ± 19 64.6 ± 12 0.04
SAPS II, median (IQR) 41 (30–54) 65 (53–78) <0.0001
SOFA, median (IQR) 7 (5–10) 10.5 (8–13) <0.0001
Creatininemia, median 
(IQR), (μmol/L)
80 (32–103) 39 (20–68) 0.01
PCT, median (IQR), (ng/
mL)
0.89 (0.20–11.4) 4.67 (1.89–24.8) 0.005
hsCRP, median (IQR), 
(mg/L)
95 (38–233) 150 (48–245) 0.24
Presepsin, median (IQR), 
(pg/mL)
871 (449–1828) 1734 (1014–3128) 0.0002
ICU length of stay, 
median (IQR), (days)
4 (2–11) 4 (2–10) 0.53
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function but only for GFR below 30 mL/min. At the onset 
of Presepsin measurement, some of our patients have an 
impaired renal function but not a severe renal failure. 
Further studies should take into account renal function, 
especially if repetitive measurements are taken, know-
ing that Presepsin has a long half-life [40]. Fifth, in the 
analysis, we did not distinguish between patients with 
gram-negative and gram-positive bacterial infections due 
to the small number of patients. However, it is to note 
that sensitivity of Presepsin is not significantly differ-
ent between gram-positive and gram-negative bacterial 
infections and even in case of fungal infection [9]. Lastly, 
we are aware that our results, although encouraging, 
may not already incite physicians to use this biomarker 
for sepsis diagnosis in ICUs. Obviously, further data and 
proofs are necessary to introduce a substantial change in 
our practice.
Conclusion
Our results demonstrated the usefulness of Presepsin lev-
els in the diagnosis and prognosis of septic shock patients 
admitted to ICUs, but its diagnostic ability remains mod-
erate as recently demonstrated [41]. Its specificity and 
predictive positive value were enhanced with the associa-
tion with PCT and should incite to evaluate their com-
bination in further studies. The diagnostic accuracy of 
Presepsin in assessment of CAP was fair. Cutoff values 
of Presepsin for both diagnosis and prognosis of SSh and 
Fig. 4 Kaplan–Meier graph showing correlation between plasma levels of Presepsin and survival in septic critically ill patients (a, b) and in critically 
ill patients with pneumonia (c, d). Survival curves according to the quartile of Presepsin (a) and to the cutoff of Presepsin (b) in septic critically ill 
patients, and in patients with pneumonia [according to the quartile of Presepsin (c) and to the cutoff of Presepsin (d)]. p values are given in each 
figure
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severe CAP have been determined herein but should be 
confirmed by further larger studies.
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